SCHEMBL538445

SCHEMBL538445

CCCOc1ccc(O)c(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.61
KMT2A Q03164 1/20 0.55
HTT P42858 1/20 0.53
PTPN11 Q06124 3/20 0.52
KAT8 Q9H7Z6 2/20 0.49
CSNK2A1 P68400 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PDE10A Q9Y233 1/20 0.48
LMNA P02545 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KLKB1 P03952 1/20 0.47
CTSB P07858 1/20 0.47
MMP9 P14780 1/20 0.47
DNMT1 P26358 1/20 0.47
DNMT3B Q9UBC3 1/20 0.47
DNMT3L Q9UJW3 1/20 0.47
DNMT3A Q9Y6K1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1576849 0.93 MCL1 (0.69) MCL1PTPN11KAT8
SCHEMBL29623897 0.93 MCL1 (0.69) MCL1PTPN11KAT8
SCHEMBL9285957 0.90 MCL1 (0.66) MCL1PTPN11KAT8
SCHEMBL29623817 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL223621 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL4653931 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL29623919 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL11694352 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL1576902 0.89 PTPN11 (0.67) MCL1PTPN11KAT8
SCHEMBL538994 0.87 KMT2A (0.55) MCL1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0987011-B1 Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use OREAL (FR) 2002-07-17 EP claimed
US-6281203-B1 ESTER OF A FATTY ACID AND GLUCOSE AND/OR ALKYLGLUCOSE, AND AN OXYETHYLENATED ETHER OF A FATTY ACID ESTER OF GLUCOSE AND/OR ALKYLGLUCOSE. L'OREAL (FR) 2001-08-28 US claimed
EP-3389595-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID HAVING TWO OR MORE ACID DISSOCIATION CONSTANTS OREAL (FR) 2025-11-05 EP disclosed
EP-3638192-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID OR BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS OREAL (FR) 2025-04-02 EP disclosed
EP-3638201-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS OREAL (FR) 2025-02-26 EP disclosed
WO-2024219512-A1 COMPOSITION COMPRISING CHITOSAN AND SALICYLIC ACID OR DERIVATIVES THEREOF L'OREAL (FR) 2024-10-24 WO disclosed
WO-2024214568-A1 WATER-BASED COSMETIC 株式会社 資生堂 2024-10-17 WO disclosed
US-12029303-B2 Method for preparation of a cosmetic kit SHISEIDO COMPANY, LTD. (JP) 2024-07-09 US disclosed
CN-110446488-B Two-dose cosmetic 株式会社资生堂 2024-07-02 CN disclosed
WO-2024135300-A1 COSMETIC COMPOSITION, COSMETIC COMPOSITION FOR SUPPRESSING DISCOLORATION, AND DISCOLORATION SUPPRESSANT 株式会社資生堂 2024-06-27 WO disclosed
US-11975093-B2 Composition comprising oil and polyion complex including cellulose-based cationic polymer with at least one fatty chain L'OREAL (FR) 2024-05-07 US disclosed
US-20030036558-A1 Substituted phenoxyacetic acids THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. 2003-02-20 US disclosed
CN-1364153-A Substituted phenoxyacetic acids INST PHARMACEUTICAL DISCOVERY (US) 2002-08-14 CN disclosed
US-6420426-B1 USED TO TREAT COMPLICATIONS FROM DIABETES MELLITUS THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2002-07-16 US disclosed
EP-1198451-A2 SUBSTITUTED PHENOXYACETIC ACIDS The Institutes for Pharmaceutical Discovery, LLC (US) 2002-04-24 EP disclosed
US-6281203-B1 ESTER OF A FATTY ACID AND GLUCOSE AND/OR ALKYLGLUCOSE, AND AN OXYETHYLENATED ETHER OF A FATTY ACID ESTER OF GLUCOSE AND/OR ALKYLGLUCOSE. L'OREAL (FR) 2001-08-28 US disclosed
WO-2001000566-A2 SUBSTITUTED PHENOXYACETIC ACIDS THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2001-01-04 WO disclosed
EP-0570230-B1 External preparation for skin SHISEIDO CO LTD (JP) 1998-09-30 EP disclosed
US-5580549-A BLEACHING; 2-HYDROXYBENZOIC ACID COMPOUND SHISEIDO CO., LTD. (JP) 1996-12-03 US disclosed
EP-0570230-A1 External preparation for skin SHISEIDO COMPANY LIMITED (JP) 1993-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11975093-B2 Composition comprising oil and polyion complex including cellulose-based cationic polymer with at least one fatty chain PRKCA, PRKCH, CUTA MCL1 4066/4885KMT2A 1749/4885HTT 3784/4885
US-20030036558-A1 Substituted phenoxyacetic acids SLC5A2, GPR119, SLC5A1 MCL1 4465/4885KMT2A 2151/4885HTT 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.